10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE 

ACT OF 1934

For the quarterly period ended September 30, 2020

  o   TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

ACT OF 1934

Commission file number:  000-55809

CANNASSIST INTERNATIONAL CORP.

 (Exact name of registrant as specified in its charter)

Delaware	82-1873116
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
855 South Mission Ave, Ste K #400, Fallbrook, California	92028
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: (760) 990-3091 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	CNSC	OTCQB

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days).    Yes  x    No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). 

Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	x	Smaller Reporting Company	x
Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(1) of the Exchange Act. ¨

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No x  

As of November 12, 2020, the Company had 18,435,000 shares of its common stock, par value $.0001 per share, issued and outstanding.

TABLE OF CONTENTS

PART I
Item 1.	Condensed Unaudited Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	15
Item 4.	Controls and Procedures	16
PART II
Item 1.	Legal Proceedings	17
Item 1A.	Risk Factors	17
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	17
Item 3.	Defaults Upon Senior Securities	17
Item 4.	Mining Safety Disclosures	17
Item 5.	Other Information	17
Item 6.	Exhibits	18
	Signatures	19

2

 PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

CANNASSIST INTERNATIONAL CORP.

INDEX TO FINANCIAL STATEMENTS

Balance Sheets as of September 30, 2020 (unaudited) and December 31, 2019	4
Statements of Operations for the three and nine months ended September 30, 2020 and 2019 (unaudited)	5
Statements of Changes in Stockholders’ Equity (Deficit) for the nine months ended September 30, 2020 and 2019 (unaudited)	6
Statements of Cash Flows for the nine months ended September 30, 2020 and 2019 (unaudited)	7
Notes to Condensed Financial Statements (unaudited)	8

3

CannAssist International Corp.

Balance Sheets

	September 30, 2020			December 31,  2019
ASSETS	(unaudited)
Current assets:
Cash	$	57,421		$	80,021
Accounts receivable		68,202			1,135
Prepaid expenses		4,308			4,145
Other asset		53			1,567
Inventory		95,866			50,592
Total assets	$	225,850		$	137,460
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable and accruals	$	243,848		$	124,796
Accounts payable – related party		20,370			9,857
Convertible notes payable, net of debt discount of $3,451		26,049			-
Customer deposits		-			54,660
Due to a related party		22,970			9,498
Loans payable		11,000			1,000
Total current liabilities		324,237			199,811
Commitments and contingencies		-			-
Stockholders’ Deficit:
Preferred stock, $0.0001 par value 20,000,000 shares authorized; none issued and outstanding		-			-
Common Stock, $0.0001 par value, 100,000,000 shares authorized; 18,435,000 issued and outstanding		1,844			1,844
Additional paid in capital		3,142,299			358,317
Accumulated deficit		(3,242,530	)		(422,512	)
Total Stockholders’ deficit		(98,387	)		(62,351	)
Total Liabilities and Stockholders’ Deficit	$	225,850		$	137,460

The accompanying notes are an integral part of these unaudited condensed financial statements.

4

CannAssist International Corp.

Statements of Operations

(Unaudited)

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2020			2019			2020			2019
Revenue	$	409,138		$	77,264		$	679,050		$	515,942
Cost of revenue		273,325			15,161			416,923			343,729
Gross margin		135,813			62,103			262,127			172,213
Operating expenses:
General and administrative		56,112			70,163			210,535			194,771
General and administrative– related party		-			3,350			-			157,450
Commissions – related party		8,527			11,395			12,900			23,962
Professional fees		29,600			56,120			86,450			161,152
Preferred stock issued for change of control		-			-			2,765,250			-
Total operating expenses		94,239			141,028			3,075,135			537,335
Income (loss) from operations		41,574			(78,925	)		(2,813,008	)		(365,122	)
Other expense:
Interest expense		(2,653	)		(1,903	)		(7,010	)		(2,419	)
Total other expense		(2,653	)		(1,903	)		(7,010	)		(2,419	)
Income (loss) before provision for income taxes		38,921			(80,828	)		(2,820,018	)		(367,541	)
Provision for income taxes		-			-			-			-
Net income (loss)	$	38,921		$	(80,828	)	$	(2,820,018	)	$	(367,541	)
Income (loss) per share, basic and diluted	$	0.00		$	(0.00	)	$	(0.15	)	$	(0.03	)
Weighted average shares outstanding, basic and diluted		18,435,000			17,878,478			18,435,000			12,431,452

The accompanying notes are an integral part of these unaudited condensed financial statements.

5

CannAssist International Corp.

Statements of Changes in Stockholders’ Deficit

For the Nine Months Ended September 30, 2020 and 2019

(Unaudited)

					Additional		Stock					Total
	Common Stock				Paid-in		Subscription		Retained			Stockholders'
	Shares		Amount		Capital		Receivable		Earnings			Deficit
Balance, December 31, 2018	12,410,000		$1,241		$13,920		$(30)		$20,294			$35,425
Cash collected on receivable								30		-			30
Net loss		-		-		-		-		(36,150	)		(36,150	)
Balance, March 31, 2019		12,410,000		1,241		13,920		-		(15,856	)		(695	)
Common stock issued for license agreement – related party		5,000,000		500		149,500		-		-			150,000
Net loss		-		-		-		-		(250,563	)		(250,563	)
Balance, June 30, 2019		17,410,000		1,741		163,420		-		(266,419	)		(101,258	)
Common stock issued for cash		850,000		85		149,915		-		-			150,000
Common stock issued for services		125,000		13		31,237		-		-			31,250
Net loss		-		-		-		-		(80,828	)		(80,828	)
Balance, September 30, 2019		18,385,000	$	1,839	$	344,572	$	-	$	(347,247	)	$	(836	)

									Additional					Total
	Preferred Stock				Common Stock				Paid-in		Retained			Stockholders'
	Shares		Amount		Shares		Amount		Capital		Earnings			Deficit
Balance, December 31, 2019		-	$	-		18,435,000	$	1,844	$	358,317	$	(422,512	)	$	(62,351	)
Preferred stock issued for change of control		1,000		-		-		-		2,765,250		-			2,765,250
Net loss		-		-		-		-		-		(2,775,369	)		(2,775,369	)
Balance, March 31, 2020		1,000		-		18,435,000		1,844		3,123,567		(3,197,881	)		(72,470	)
Warrants issued		-		-		-		-		9,022		-			9,022
Net loss		-		-		-		-		-		(83,570	)		(83,570	)
Balance, June 30, 2020		1,000	$	-		18,435,000		1,844		3,132,589		(3,281,451	)		(147,018	)
Warrants issued		-		-		-		-		9,710		-			9,710
Net loss		-		-		-		-		-		38,921			38,921
Balance, September 30, 2020		1,000	$	-		18,435,000	$	1,844	$	3,142,299	$	(3,242,530	)	$	(98,387	)

The accompanying notes are an integral part of these unaudited condensed financial statements. 

6

CannAssist International Corp.

Statements of Cash Flows

(Unaudited)

	For the Nine Months Ended September 30,
	2020			2019
Cash flows from operating activities:
Net loss	$	(2,820,018	)	$	(367,541	)
Adjustments to reconcile net loss to net cash used in operating activities:
Preferred stock issued for change of control		2,765,250			-
Warrant expense		12,520			-
Debt discount		2,763
Common stock issued for licensing expense – related party		-			150,000
Common stock issued for services		-			31,250
Changes in Operating Assets and Liabilities:
Accounts receivable		(67,066	)		(2,472	)
Inventory		(45,275	)		(19,971	)
Prepaid expenses and other assets		1,351			8,045
Accounts payable and accrued liabilities		129,564			68,020
Customer deposits		(54,660	)		(456	)
Net cash used by operating activities		(75,571	)		(133,125	)
Cash flows from Investing activities:		-			-
Cash flows from Financing activities:
Proceeds from loans - related party		18,981			12,450
Repayment of related party loans		(5,510	)		(11,618	)
Proceeds from loans payable		10,000			-
Proceeds from convertible loans payable		29,500			-
Proceeds from sale of common stock		-			150,000
Proceeds from stock subscription receivable		-			30
Net cash provided by financing activities		52,971			150,862
Net decrease in cash		(22,600	)		17,737
Cash, beginning of period		80,021			67,351
Cash, end of period	$	57,421		$	85,088
Supplemental Disclosure of Cash Flow Information:
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-

The accompanying notes are an integral part of these unaudited condensed financial statements.

7

CANNASSIST INTERNATIONAL CORP.

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2020

NOTE 1 - DESCRIPTION OF BUSINESS AND HISTORY

Description of business

CannAssist International Corp. (the “Company” or “CannAssist”) was incorporated on May 17, 2017 under the laws of the state of Delaware under the name Iris Grove Acquisition Corporation to engage in any lawful corporate undertaking, including, but not limited to, selected mergers and acquisitions. On May 23, 2018 the Company changed its name to CannAssist International Corporation.

On June 18, 2018, the Company cancelled all 20,000,000 shares of its issued and outstanding stock and issued 3,000,000 shares of common stock pursuant to Section 4(a)(2) of the Securities Act of 1933 at par representing 100% of the total outstanding common stock at the time. With the issuance of the stock and the redemption of the 20,000,000 shares of stock, the Company effected a change in its control and the new majority shareholder was elected as the new management of the Company.

On July 12, 2018, the “Company, entered into a share exchange acquisition agreement with Xceptor LLC, a private company organized under the laws of Wyoming (“Xceptor”). The Acquisition was effected by the Company through the exchange of all the outstanding membership interests of Xceptor for 3,000,000 shares of common stock of the Company, valued at $0.0001 per share. At the time of the Acquisition, there was one shareholder of the Company who was also a shareholder and manager of Xceptor. Xceptor has become a wholly owned subsidiary of the Company and the Company has taken over its operations and business plan. Prior to the Acquisition, the Company had no ongoing business or operations. Since the Company and Xceptor were entities under common control prior to the Acquisition, the transaction is accounted for as a restructuring transaction. The Company has recast prior period financial statements to reflect the conveyance of Xceptor’s common shares as if the restructuring transaction had occurred as of the earliest date of the financial statements.

CannAssist produces and sells products formulated using its cannabidiol ("CBD") product, “Cibidinol,” which is formulated based on a process developed by its founder Mark Palumbo. CBD is a non-psychoactive compound found in hemp. CannAssist’s initial research and development work, aimed at enhancing the bioavailability of desired molecular structures, resulted in the creation of a line of CBD products, most notably its CBD product, Cibidinol. Cibidinol will be available in a line of consumable and topical products that the Company believes will make enhanced CBD products more available and accessible to consumers.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Accounts Receivable

Revenues that have been recognized but not yet received are recorded as accounts receivable. Losses on receivables will be recognized when it is more likely than not that a receivable will not be collected. An allowance for estimated uncollectible amounts will be recognized to reduce the amount of receivables to its net realizable value when needed. The allowance for uncollectible amounts is evaluated quarterly.

8

CANNASSIST INTERNATIONAL CORP.

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2020

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Revenue Recognition

Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time, typically upon delivery.

The Company recognizes revenue when product is shipped. The Company will often receive payment and/or pay for the cost of goods prior to shipping. When this occurs, the result is both a prepaid for the supplies to be used in their product and a customer deposit. As of December 31, 2019, the Company has both a prepaid expense of $4,145 and customer deposits of $54,660, for orders to be shipped in Q1, 2020.

Cost of Sales

Cost of sales is determined on the basis of the cost of production or the purchase of goods, adjusted for the variation of inventory Cost of sale is recognized as the direct cost of products or services sold during the period.

 Recently issued accounting pronouncements

The Company has implemented all new accounting pronouncements that are in effect.  These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

NOTE 3 - GOING CONCERN

The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has generated revenues of $679,050 during the nine months ended September 30, 2020 and had a net loss of $2,820,018 for nine months ended September 30, 2020, which consisted of a $2,765,250 non-cash expense for the issuance of preferred stock. The Company has an accumulated deficit of $3,242,530 as of September 30, 2020. The Company requires capital for its contemplated operational and marketing activities. The obtainment of additional financing, through an initial capital raise, the successful development of the Company’s contemplated plan of operations, and its transition to the attainment of continued profitable operations are necessary for the Company to continue operations. There is no guarantee that the Company will be able to obtain the necessary financing or profitable operations. These conditions and the ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

NOTE 4 – LOANS PAYABLE

On October 11, 2017, the Company received a $1,000 loan from a third party. The loan is unsecured, due on demand and non-interest bearing.

On June 29, 2020, the Company received a $10,000 loan from a third party. The loan is unsecured, due on demand and non-interest bearing.

9

CANNASSIST INTERNATIONAL CORP.

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2020

NOTE 5 – CONVERTIBLE NOTES PAYABLE

On June 2, 2020, the Company issued a convertible note payable to a third party for $10,000. The note is unsecured, non-interest bearing and is due and payable in six months. If the loan is not repaid by the due date is can be converted into shares of common stock at $0.25 per share. In addition, the Company issued warrants to purchase 13,500 shares of common stock. The warrants have an exercise price of $0.50 and expire in five years.

On June 12, 2020, the Company issued a convertible note payable to a third party for $5,000. The note is unsecured, non-interest bearing and is due and payable in six months. If the loan is not repaid by the due date is can be converted into shares of common stock at $0.25 per share. In addition, the Company issued warrants to purchase 6,667 shares of common stock. The warrants have an exercise price of $0.50 and expire in five years.

During July and August 2020, the Company issued a convertible notes payable to third parties for a total of $14,500. The notes are all unsecured, non-interest bearing and due and payable in six months. If the loans are not repaid by the due date they can be converted into shares of common stock at $0.25 per share. In addition, the Company issued warrants to purchase 20,669 shares of common stock. The warrants have an exercise price of $0.50 and expire in five years.

The above notes are shown net of $3,451 of debt discount.

NOTE 6 – RELATED PARTY TRANSACTIONS

Marla Palumbo has advanced the Company a limited amount of funds to cover some general operating expenses and travel costs. These advances are unsecured, due on demand and non-interest bearing. As of September 30, 2020, and December 31, 2019, the balance due to Ms. Palumbo for cash advances is $22,670 and $9,498, respectively. Ms. Palumbo is the President of the Company and wife of the CEO, Mark Palumbo.

During the nine months ended September 30, 2020 and 2019, the Company paid sales commissions of $12,900 and $23,962, respectively, to EME Ltd.

During the nine months ended September 30, 2020 and 2019, respectively, the Company incurred $0 and $7,450 of expense for Matthew Palumbo for product design services. Matthew Palumbo is the son of Mark Palumbo, CEO.

On April 29, 2019, the Company entered into a Technology License Agreement with Mark Palumbo (“Licensor”) whereby the Licensor granted to the Company an exclusive worldwide license (the “License”) to use, market, promote and distribute certain technology related to a provisional patent application for a “Process for creating Carbohydrate Complexes with Cannabinoids and other Hydrophobic Molecules in large scale,” related patent applications, related trade-secrets and associated knowhow, including methods, techniques, specifications, procedures, information, systems, knowledge and business processes required to practice and carry on business in the field of data collection, security and management (the “Technology”). The initial term of the License is 5-years (the “Initial Term”) and shall automatically be renewed for successive 1-year terms (each, a “Renewal Term”) unless the Company elects to terminate the License by giving 30 days’ written notice prior to commencement of a Renewal Term. In exchange for the License of the Technology, the Company shall issue to the Licensor 5,000,000 restricted shares of its common stock, valued at par value per share, at the effective date of the agreement, and shall issue to the Licensor an additional 1,000,000 restricted shares of its common stock, valued at par value per share, at the commencement of each Renewal Term.

On March 30, 2020, the Company issued 1,000 shares of its Series A Preferred Stock to Mark Palumbo, an officer and director of the Company. Based on the rights of the designation the shares of preferred stock were value at 60% of the value of the total common stock outstanding. The shares of common stock have a current fair value of $0.25 per shares resulting in total non-cash expense of $2,765,250.

10

CANNASSIST INTERNATIONAL CORP.

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2020

NOTE 7 – PREFERRED STOCK

The Company has designated 1,000 shares of Series A Preferred Stock. The shares of Series A Preferred Stock have a par value of $0.0001 per share. The Series A Preferred Shares do not have a dividend rate or liquidation preference and are not convertible into shares of common stock. Series A Preferred Stock, voting together as a class, have the right to vote 60% of the Company’s voting shares on any and all shareholder matters (the “Majority Voting Rights”). Additionally, the Company shall not adopt any amendments to the Company’s Bylaws, Articles of Incorporation, as amended, make any changes to the Certificate of Designations establishing the Series A Preferred Stock, or effect any reclassification of the Series A Preferred Stock, without the affirmative vote of at least a majority of the outstanding shares of Series A Preferred Stock. However, the Company may, by any means authorized by law and without any vote of the holders of shares of Series A Preferred Stock, make technical, corrective, administrative or similar changes to such Certificate of Designations that do not, individually or in the aggregate, adversely affect the rights or preferences of the holders of shares of Series A Preferred Stock. Other than the Majority Voting Rights, the Series A Preferred Stock does not have any other dividend, liquidation, conversion, or redemption rights, whatsoever.

NOTE 8 – WARRANTS

On April 1, 2020, the Company entered into an agreement with an independent consultant pursuant to which the consultant shall be paid a cash monthly retainer of $5,000 a month and shall be issued 110,000 warrants to purchase shares of the common stock of the Company at an exercise price equal to $0.25 per share, subject to certain conditions regarding vesting. This agreement has a term of 12 months and shall be automatically renewed on a month to month basis unless terminated upon 30 days’ written notice.

The warrants were evaluated for purposes of classification between liability and equity. The warrants do not contain features that would require a liability classification and are therefore considered equity. The warrants were fair valued at $25,038. The expense is being amortized over the one-year term of the agreement. The Black Scholes pricing model was used to estimate the fair value of the Warrants issued with the following inputs:

Warrants		110,000
Share price	$	0.25
Exercise Price	$	0.25
Term		10 years
Volatility		103.5	%
Risk Free Interest Rate		2.49	%
Dividend rate		-

During the nine months ended September 30, 2020, the Company issued 40,836 warrants in conjunction with the issuance of convertible promissory notes (Note 5). The warrants have an exercise price of $0.50 and expire in five years. Using the fair value calculation, the relative fair value between the debt issued and the warrants was calculated to determine the warrants recorded equity amount of 6,212, accounted for in additional paid in capital.

The Black Scholes pricing model was used to estimate the fair value of the warrants issued with the following inputs: 

Warrants		40,836
Share price	$	0.25
Exercise Price	$	0.25
Term		5 years
Volatility		103.5 – 111.89	%
Risk Free Interest Rate		0.22 - 1.88	%
Dividend rate		-

11

CANNASSIST INTERNATIONAL CORP.

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2020

NOTE 8 – WARRANTS (CONTINUED)

A summary of the status of the Company’s outstanding stock warrants and changes during the year is presented below:

Activity for the nine months ended September 30, 2020 is as follows: 

	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contract Term		Aggregate Intrinsic Value
Outstanding at December 31, 2019	-		-		-
Granted		150,836	$	0.25		8.22	$	-
Expired		-	$	-		-	$	-
Exercised		-	$	-		-	$	-
Outstanding at September 30, 2020		150,836	$	0.25		8.22	$	-
Exercisable at September 30, 2020		76,000	$	0.25		8.22	$	-

Range of Exercise Prices		Number Outstanding 9/30/2020		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price
$	0.25		150,836		8.22 years	$	0.25

NOTE 9 – SUBSEQUENT EVENTS

In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were available to be issued and has determined that it does not have any material subsequent events to disclose in these financial statements.

12

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following information should be read in conjunction with our financial statements and related notes thereto included in Part I, Item 1, above.

Forward Looking Statements

Certain matters discussed herein are forward-looking statements. Such forward-looking statements contained in this Form 10-Q involve risks and uncertainties, including statements as to:

·our future strategic plans

·our future operating results;

·our business prospects;

·our contractual arrangements and relationships with third parties;

·the dependence of our future success on the general economy;

·our possible future financings; and

·the adequacy of our cash resources and working capital.

These forward-looking statements can generally be identified as such because the context of the statement will include words such as we “believe,” “anticipate,” “expect,” “estimate” or words of similar meaning. Similarly, statements that describe our future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties which are described in close proximity to such statements and which could cause actual results to differ materially from those anticipated. Shareholders, potential investors and other readers are urged to consider these factors in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included herein are only made as of the date of this Form 10-Q, and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Executive Overview

CannAssist International Corporation (“CannAssist” or the "Company") was incorporated on May 17, 2017 under the laws of the State of Delaware.

CannAssist produces and sells its cannabidiol ("CBD") product, “Cibidinol,” which is formulated based on a process developed by its founder Mark Palumbo. CBD is a non-psychoactive compound found in hemp. CannAssist’s initial research and development work, aimed at enhancing the bioavailability of desired molecular structures, resulted in the creation of a line of CBD products, most notably its CBD product, Cibidinol. Cibidinol will be available in a line of consumable and topical products that the Company believes will make enhanced CBD products more available and accessible to consumers.

The Company's independent auditors have issued a report raising substantial doubt about the Company's ability to continue as a going concern. At present, the Company has no operations and the continuation of the Company as a going concern is dependent upon financial support from its stockholders, its ability to obtain necessary equity financing to continue operations and/or to successfully locate and negotiate with a business entity for the combination of that target company with it.

Results of Operation for the Three Months Ended September 30, 2020 and 2019

Revenues

For the three months ended September 30, 2020, the Company had revenues of $409,138, cost of revenue of $273,325 and a gross margin of $135,813. In comparison, for the three months ended September 30, 2019, the Company had revenue of $77,264, cost of revenue of $ 15,161 and a gross margin of $62,103. The increase in revenue, cost of revenue and gross margin is from a change in the demand for our products derived from expanded commercialization of our products.

General and administrative expenses

General and administrative expenses (“G&A”) were $56,112 for the three months ended September 30, 2020 compared to $70,163 for the three months ended September 30, 2019. The decrease in general and administrative expenses are related to decreases in expenses related to product testing, supplies and materials, insurance and travel.

13

General and administrative expenses to a related party, were $0 for the three months ended September 30, 2020 compared to $3,350 for the three months ended September 30, 2019. General and administrative expenses to a related party, which were incurred for product design services provided by the son of the CEO, decreased because they were not recurring expenses.

Commissions

Commission expense was $8,527 for the three months ended September 30, 2020 compared to $11,395 for the three months ended September 30, 2019. Commission expense was paid to EME, LLC, a related party, and has decreased in the current period in conjunction with the decrease in sales attributable to customers managed by EME, LLC.

Professional fees

Professional fees were $29,600 for the three months ended September 30, 2020 compared to $56,120 for the three months ended September 30, 2019. Professional fees consist of audit, accounting, consulting and legal fees. The fees have decreased with the decrease in services required to comply with SEC filing requirements during the relevant periods.

Other expense

For the three months ended September 30, 2020 we incurred $2,653 of credit card interest expense compared to $ 1,903 for three months ended September 30, 2019.

Net Income

For the three months ended September 30, 2020, we realized net income of $38,921 as compared to net loss of $ 80,828 for three months ended September 30, 2019. The increase from a net loss in the prior period to net income in the current period is the result of higher revenue combined with decreased expenses.

Results of Operation for the Nine Months Ended September 30, 2020 and 2019

Revenues

For the nine months ended September 30, 2020, the Company had revenues of $679,050, cost of revenue of $416,923 and gross margin of $262,127. In comparison, for the nine months ended September 30, 2019, the Company had revenue of $515,942, cost of revenue of $343,729 and gross margin of $172,213. The increase in revenue, cost of revenue and gross margin is from a change in the demand for our products derived from expanded commercialization of our products.

General and administrative expenses

General and administrative expenses were $210,535 for the nine months ended September 30, 2020 compared to $194,771 for the nine months ended September 30, 2019. In general G&A expenses have increased with the increase in business activity.

General and administrative expenses to a related party, were $0 for the nine months ended September 30, 2020 compared to $157,450 for the nine months ended September 30, 2019. General and administrative expenses to a related party, which were a result of the issuance of 5,000,000 shares of common stock for a licensing agreement for total non-cash expense of $150,000 and for product design services provided by the son of the CEO, have decreased because they were not recurring expenses.

Commissions

Commission expense was $12,900 for the nine months ended September 30, 2020 compared to $23,962 for the nine months ended September 30, 2019. Commission expense was paid to EME, LLC, a related party, and has decreased in the current period in conjunction with the decrease in sales attributable to customers managed by EME, LLC.

Professional fees

Professional fees were $86,450 for the nine months ended September 30, 2020 compared to $161,152 for the nine months ended September 30, 2019. Professional fees consist of audit, accounting, consulting and legal fees. The fees have decreased with the decrease in services required to comply with SEC filing requirements during the relevant periods.

Other expense

For the nine months ended September 30, 2020 we incurred $7,010 of credit card interest expense compared to $2,419 for nine months ended September 30, 2019.

14

Net Loss

For the nine months ended September 30, 2020, we realized a net loss of $2,820,018 as compared to net loss of $367,541 for the nine months ended September 30, 2019. The increase in net loss in the current period is primarily due to the expense incurred in connection with the issuance of preferred stock.

Liquidity and Capital Resources

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has generated revenues of $679,050 for the nine months ended September 30, 2020 and had a net loss of $2,820,018 for the nine months ended September 30, 2020. The Company has an accumulated deficit of $3,242,530 as of September 30, 2020. The Company requires capital for its contemplated operational and marketing activities. The obtainment of additional financing, through an initial capital raise, the successful development of the Company’s contemplated plan of operations, and its transition to the attainment of continued profitable operations are necessary for the Company to continue operations. There is no guarantee that the Company will be able to obtain the necessary financing or profitable operations. These conditions and the ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

The Company used $75,571 of cash from operations for the nine months ended September 30, 2020. Net cash provided by financing activities for the nine months ended September 30, 2020 was $52,971.

As of September 30, 2020, the Company had $57,421 in cash.

Critical Accounting Estimates and Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Note 2 to the Financial Statements describes the significant accounting policies and methods used in the preparation of the Financial Statements. Estimates are used for, but not limited to, contingencies and taxes.  Actual results could differ materially from those estimates. The following critical accounting policies are impacted significantly by judgments, assumptions, and estimates used in the preparation of the Financial Statements.

We are subject to various loss contingencies arising in the ordinary course of business.  We consider the likelihood of loss or impairment of an asset or the incurrence of a liability, as well as our ability to reasonably estimate the amount of loss in determining loss contingencies.  An estimated loss contingency is accrued when management concludes that it is probable that an asset has been impaired, or a liability has been incurred and the amount of the loss can be reasonably estimated.  We regularly evaluate current information available to us to determine whether such accruals should be adjusted.

Off-Balance Sheet Arrangements 

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

Recent Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable to smaller reporting companies.

15

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to be effective in providing reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the “SEC”), and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure. Our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, they concluded that our disclosure controls and procedures were not effective for the quarterly period ended September 30, 2020.

The following aspects of the Company were noted as potential material weaknesses:

· timely and accurate reconciliation of accounts

· lack of segregation of duties

In designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute assurance of achieving the desired objectives. Also, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs.

Changes in Internal Controls

Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that no change occurred in the Company's internal controls over financial reporting during the quarter ended September 30, 2020, that has materially affected, or is reasonably likely to materially affect, the Company's internal controls over financial reporting.

16

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

There are not presently any material pending legal proceedings to which the Company is a party or as to which any of our property is subject, and no such proceedings are known to the Company to be threatened or contemplated against it.

ITEM 1A. RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, are not required to provide the information under this Item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On June 2, 2020, the Company issued a convertible note payable to a third party for $10,000. The note is unsecured, non-interest bearing and is due and payable in six months. If the loan is not repaid by the due date is can be converted into shares of common stock at $0.25 per share. In addition, the Company issued warrants to purchase 13,500 shares of common stock. The warrants have an exercise price of $0.50 and expire in five years. The issuance of the promissory notes and warrants were each exempt from registration under Section 4(a)(2) and Rule 506(b) of Regulation D as promulgated under the Securities Act.

On June 12, 2020, the Company issued a convertible note payable to a third party for $5,000. The note is unsecured, non-interest bearing and is due and payable in six months. If the loan is not repaid by the due date is can be converted into shares of common stock at $0.25 per share. In addition, the Company issued warrants to purchase 6,667 shares of common stock. The warrants have an exercise price of $0.50 and expire in five years. The issuance of the promissory notes and warrants were each exempt from registration under Section 4(a)(2) and Rule 506(b) of Regulation D as promulgated under the Securities Act.

During July and August 2020, the Company issued convertible notes payable to third parties for a total of $14,500. The notes are all unsecured, non-interest bearing and due and payable in six months. If the loans are not repaid by the due date, they can be converted into shares of common stock at $0.25 per share. In addition, the Company issued warrants to purchase 20,669 shares of common stock. The warrants have an exercise price of $0.50 and expire in five years. The issuance of the promissory notes and warrants were each exempt from registration under Section 4(a)(2) and Rule 506(b) of Regulation D as promulgated under the Securities Act.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINING SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION.

None

17

ITEM 6. EXHIBITS

No.	Description
31.1	Chief Executive Officer Section 302 Certification
31.2	Chief Financial Officer Section 302 Certification
32.1	Section 906 Certification
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Label Linkbase Document
101.PRE	XBRL Taxonomy Presentation Linkbase Document

18

SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CANNASSIST INTERNATIONAL CORPORATION

Dated: November 12, 2020	By:  /s/ Mark Palumbo Mark Palumbo Chief Executive Officer
	By: /s/ Mark Palumbo Mark Palumbo Chief Financial Officer

19

EX-31.1

Exhibit 31.1

CHIEF EXECUTIVE OFFICER

I, Mark Palumbo, hereby certify that:

(1) I have reviewed this Quarterly Report on Form 10-Q for the period ending September 30, 2020 of CannAssist International Corporation;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated:  November 12, 2020 /s/ Mark Palumbo Mark Palumbo Chief Executive Officer

EX-31.2

Exhibit 31.2

CHIEF FINANCIAL OFFICER

I, Mark Palumbo, hereby certify that:

(1) I have reviewed this Quarterly Report on Form 10-Q for the period ending September 30, 2020 of CannAssist International Corporation;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated November 12, 2020 /s/ Mark Palumbo Mark Palumbo Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officers of CannAssist International Corporation., a Delaware corporation (the "Company"), do hereby certify, to the best of their knowledge, that:

1.     The Quarterly Report on Form 10-Q for the period ending September 30, 2020 (the "Report") of the Company complies in all material respects with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.     The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.  

Dated:  November 12, 2020 /s/ Mark Palumbo Mark Palumbo Chief Executive Officer

Dated:  November 12, 2020 /s/ Mark Palumbo Mark Palumbo Chief Financial Officer

XML

Cover - shares	9 Months Ended
	Sep. 30, 2020	Nov. 12, 2020
Cover [Abstract]
Entity Registrant Name	CannAssist International Corp
Entity Central Index Key	0001709542
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity File Number	000-55809
Entity Incorporation State Country Code	DE
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		18,435,000
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020

XML

Balance Sheets (unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash	$ 57,421	$ 80,021
Accounts receivable	68,202	1,135
Prepaid expenses	4,308	4,145
Other asset	53	1,567
Inventory	95,866	50,592
Total assets	225,850	137,460
Current liabilities:
Accounts payable and accruals	243,848	124,796
Accounts payable - related party	20,370	9,857
Convertible notes payable, net of debt discount of $3,451	26,049
Customer deposits		54,660
Due to a related party	22,970	9,498
Loans payable	11,000	1,000
Total current liabilities	324,237	199,811
Commitments and contingencies
Stockholders' Deficit:
Preferred stock, $0.0001 par value 20,000,000 shares authorized; none issued and outstanding
Common Stock, $0.0001 par value, 100,000,000 shares authorized; 18,435,000 issued and outstanding	1,844	1,844
Additional paid in capital	3,142,299	358,317
Accumulated deficit	(3,242,530)	(422,512)
Total Stockholders' deficit	(98,387)	(62,351)
Total Liabilities and Stockholders' Deficit	$ 225,850	$ 137,460

XML

Balance Sheets (unaudited) (Parenthetical) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Convertible notes payable, net of debt discount	$ 3,451	$ 3,451
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized	20,000,000	20,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized	100,000,000	100,000,000
Common stock, issued	18,435,000	18,435,000
Common stock, outstanding	18,435,000	18,435,000

XML

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenue	$ 409,138	$ 77,264	$ 679,050	$ 515,942
Cost of revenue	273,325	15,161	416,923	343,729
Gross margin	135,813	62,103	262,127	172,213
Operating expenses:
General and administrative	56,112	70,163	210,535	194,771
General and administrative- related party		3,350		157,450
Commissions - related party	8,527	11,395	12,900	23,962
Professional fees	29,600	56,120	86,450	161,152
Preferred stock issued for change of control			2,765,250
Total operating expenses	94,239	141,028	3,075,135	537,335
Income (loss) from operations	41,574	(78,925)	(2,813,008)	(365,122)
Other expense:
Interest expense	(2,653)	(1,903)	(7,010)	(2,419)
Total other expense	(2,653)	(1,903)	(7,010)	(2,419)
Income (loss) before provision for income taxes	38,921	(80,828)	(2,820,018)	(367,541)
Provision for income taxes
Net income (loss)	$ 38,921	$ (80,828)	$ (2,820,018)	$ (367,541)
Income (loss) per share, basic and diluted (in dollars per share)	$ 0.00	$ (0.00)	$ (0.15)	$ (0.03)
Weighted average shares outstanding, basic and diluted (in shares)	18,435,000	17,878,478	18,435,000	12,431,452

XML

Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock Subscription Receivable [Member]	Retained Earnings [Member]	Total
Balance at the beginning at Dec. 31, 2018		$ 1,241	$ 13,920	$ (30)	$ 20,294	$ 35,425
Balance at the beginning (in shares) at Dec. 31, 2018		12,410,000
Increase Decrease In Stockholders Equity [Roll Forward]
Cash collected on receivable				30		30
Net loss					(36,150)	(36,150)
Balance at the end at Mar. 31, 2019		$ 1,241	13,920		(15,856)	(695)
Balance at the end (in shares) at Mar. 31, 2019		12,410,000
Balance at the beginning at Dec. 31, 2018		$ 1,241	13,920	(30)	20,294	35,425
Balance at the beginning (in shares) at Dec. 31, 2018		12,410,000
Increase Decrease In Stockholders Equity [Roll Forward]
Net loss						(367,541)
Balance at the end at Sep. 30, 2019		$ 1,839	344,572		(347,247)	(836)
Balance at the end (in shares) at Sep. 30, 2019		18,385,000
Balance at the beginning at Mar. 31, 2019		$ 1,241	13,920		(15,856)	(695)
Balance at the beginning (in shares) at Mar. 31, 2019		12,410,000
Increase Decrease In Stockholders Equity [Roll Forward]
Common stock issued for license agreement - related party		$ 500	149,500			150,000
Common stock issued for license agreement - related party (in shares)		5,000,000
Net loss					(250,563)	(250,563)
Balance at the end at Jun. 30, 2019		$ 1,741	163,420		(266,419)	(101,258)
Balance at the end (in shares) at Jun. 30, 2019		17,410,000
Increase Decrease In Stockholders Equity [Roll Forward]
Common stock issued for cash		$ 85	149,915			150,000
Common stock issued for cash (in shares)		850,000
Common stock issued for services		$ 13	31,237			31,250
Common stock issued for services (in shares)		125,000
Net loss					(80,828)	(80,828)
Balance at the end at Sep. 30, 2019		$ 1,839	344,572		(347,247)	(836)
Balance at the end (in shares) at Sep. 30, 2019		18,385,000
Balance at the beginning at Dec. 31, 2019		$ 1,844	358,317		(422,512)	(62,351)
Balance at the beginning (in shares) at Dec. 31, 2019		18,435,000
Increase Decrease In Stockholders Equity [Roll Forward]
Preferred stock issued for change of control			2,765,250			2,765,250
Preferred stock issued for change of control (in shares)	1,000
Net loss					(2,775,369)	(2,775,369)
Balance at the end at Mar. 31, 2020		$ 1,844	3,123,567		(3,197,881)	(72,470)
Balance at the end (in shares) at Mar. 31, 2020	1,000	18,435,000
Balance at the beginning at Dec. 31, 2019		$ 1,844	358,317		(422,512)	(62,351)
Balance at the beginning (in shares) at Dec. 31, 2019		18,435,000
Increase Decrease In Stockholders Equity [Roll Forward]
Net loss						(2,820,018)
Balance at the end at Sep. 30, 2020		$ 1,844	3,142,299		(3,242,530)	(98,387)
Balance at the end (in shares) at Sep. 30, 2020	1,000	18,435,000
Balance at the beginning at Mar. 31, 2020		$ 1,844	3,123,567		(3,197,881)	(72,470)
Balance at the beginning (in shares) at Mar. 31, 2020	1,000	18,435,000
Increase Decrease In Stockholders Equity [Roll Forward]
Warrants issued			9,022			9,022
Net loss					(83,570)	(83,570)
Balance at the end at Jun. 30, 2020		$ 1,844	3,132,589		(3,281,451)	(147,018)
Balance at the end (in shares) at Jun. 30, 2020	1,000	18,435,000
Increase Decrease In Stockholders Equity [Roll Forward]
Warrants issued			9,710			9,710
Net loss					38,921	38,921
Balance at the end at Sep. 30, 2020		$ 1,844	$ 3,142,299		$ (3,242,530)	$ (98,387)
Balance at the end (in shares) at Sep. 30, 2020	1,000	18,435,000

XML

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (2,820,018)	$ (367,541)
Adjustments to reconcile net loss to net cash used in operating activities:
Preferred stock issued for change of control	2,765,250
Warrant expense	12,520
Debt discount	2,763
Common stock issued for licensing expense - related party		150,000
Common stock issued for services		31,250
Changes in Operating Assets and Liabilities:
Accounts receivable	(67,066)	(2,472)
Inventory	(45,275)	(19,971)
Prepaid expenses and other assets	1,351	8,045
Accounts payable and accrued liabilities	129,564	68,020
Customer deposits	(54,660)	(456)
Net cash used by operating activities	(75,571)	(133,125)
Cash flows from Investing activities:
Cash flows from Financing activities:
Proceeds from loans - related party	18,981	12,450
Repayment of related party loans	(5,510)	(11,618)
Proceeds from loans payable	10,000
Proceeds from convertible loans payable	29,500
Proceeds from sale of common stock		150,000
Proceeds from stock subscription receivable		30
Net cash provided by financing activities	52,971	150,862
Net decrease in cash	(22,600)	17,737
Cash, beginning of period	80,021	67,351
Cash, end of period	57,421	85,088
Supplemental Disclosure of Cash Flow Information:
Cash paid for interest
Cash paid for taxes

XML

DESCRIPTION OF BUSINESS AND HISTORY

9 Months Ended

Sep. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

DESCRIPTION OF BUSINESS AND HISTORY

NOTE 1 - DESCRIPTION OF BUSINESS AND HISTORY

Description of business

CannAssist International Corp. (the “Company” or “CannAssist”) was incorporated on May 17, 2017 under the laws of the state of Delaware under the name Iris Grove Acquisition Corporation to engage in any lawful corporate undertaking, including, but not limited to, selected mergers and acquisitions. On May 23, 2018 the Company changed its name to CannAssist International Corporation.

On June 18, 2018, the Company cancelled all 20,000,000 shares of its issued and outstanding stock and issued 3,000,000 shares of common stock pursuant to Section 4(a)(2) of the Securities Act of 1933 at par representing 100% of the total outstanding common stock at the time. With the issuance of the stock and the redemption of the 20,000,000 shares of stock, the Company effected a change in its control and the new majority shareholder was elected as the new management of the Company.

On July 12, 2018, the “Company, entered into a share exchange acquisition agreement with Xceptor LLC, a private company organized under the laws of Wyoming (“Xceptor”). The Acquisition was effected by the Company through the exchange of all the outstanding membership interests of Xceptor for 3,000,000 shares of common stock of the Company, valued at $0.0001 per share. At the time of the Acquisition, there was one shareholder of the Company who was also a shareholder and manager of Xceptor. Xceptor has become a wholly owned subsidiary of the Company and the Company has taken over its operations and business plan. Prior to the Acquisition, the Company had no ongoing business or operations. Since the Company and Xceptor were entities under common control prior to the Acquisition, the transaction is accounted for as a restructuring transaction. The Company has recast prior period financial statements to reflect the conveyance of Xceptor’s common shares as if the restructuring transaction had occurred as of the earliest date of the financial statements.

CannAssist produces and sells products formulated using its cannabidiol ("CBD") product, “Cibidinol,” which is formulated based on a process developed by its founder Mark Palumbo. CBD is a non-psychoactive compound found in hemp. CannAssist’s initial research and development work, aimed at enhancing the bioavailability of desired molecular structures, resulted in the creation of a line of CBD products, most notably its CBD product, Cibidinol. Cibidinol will be available in a line of consumable and topical products that the Company believes will make enhanced CBD products more available and accessible to consumers. 

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Accounts Receivable

Revenues that have been recognized but not yet received are recorded as accounts receivable. Losses on receivables will be recognized when it is more likely than not that a receivable will not be collected. An allowance for estimated uncollectible amounts will be recognized to reduce the amount of receivables to its net realizable value when needed. The allowance for uncollectible amounts is evaluated quarterly.

Revenue Recognition

Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time, typically upon delivery.

The Company recognizes revenue when product is shipped. The Company will often receive payment and/or pay for the cost of goods prior to shipping. When this occurs, the result is both a prepaid for the supplies to be used in their product and a customer deposit. As of December 31, 2019, the Company has both a prepaid expense of $4,145 and customer deposits of $54,660, for orders to be shipped in Q1, 2020.

Cost of Sales

Cost of sales is determined on the basis of the cost of production or the purchase of goods, adjusted for the variation of inventory Cost of sale is recognized as the direct cost of products or services sold during the period.

 Recently issued accounting pronouncements

The Company has implemented all new accounting pronouncements that are in effect.  These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. 

XML

GOING CONCERN

9 Months Ended

Sep. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN

NOTE 3 - GOING CONCERN

The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has generated revenues of $679,050 during the nine months ended September 30, 2020 and had a net loss of $2,820,018 for nine months ended September 30, 2020, which consisted of a $2,765,250 non-cash expense for the issuance of preferred stock. The Company has an accumulated deficit of $3,242,530 as of September 30, 2020. The Company requires capital for its contemplated operational and marketing activities. The obtainment of additional financing, through an initial capital raise, the successful development of the Company’s contemplated plan of operations, and its transition to the attainment of continued profitable operations are necessary for the Company to continue operations. There is no guarantee that the Company will be able to obtain the necessary financing or profitable operations. These conditions and the ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

XML

LOANS PAYABLE

9 Months Ended

Sep. 30, 2020

Loans Payable [Abstract]

LOANS PAYABLE

NOTE 4 – LOANS PAYABLE

On October 11, 2017, the Company received a $1,000 loan from a third party. The loan is unsecured, due on demand and non-interest bearing.

On June 29, 2020, the Company received a $10,000 loan from a third party. The loan is unsecured, due on demand and non-interest bearing. 

XML

CONVERTIBLE NOTES PAYABLE

9 Months Ended

Sep. 30, 2020

Convertible Notes Payable [Abstract]

CONVERTIBLE NOTES PAYABLE

NOTE 5 – CONVERTIBLE NOTES PAYABLE

On June 2, 2020, the Company issued a convertible note payable to a third party for $10,000. The note is unsecured, non-interest bearing and is due and payable in six months. If the loan is not repaid by the due date is can be converted into shares of common stock at $0.25 per share. In addition, the Company issued warrants to purchase 13,500 shares of common stock. The warrants have an exercise price of $0.50 and expire in five years.

On June 12, 2020, the Company issued a convertible note payable to a third party for $5,000. The note is unsecured, non-interest bearing and is due and payable in six months. If the loan is not repaid by the due date is can be converted into shares of common stock at $0.25 per share. In addition, the Company issued warrants to purchase 6,667 shares of common stock. The warrants have an exercise price of $0.50 and expire in five years.

During July and August 2020, the Company issued a convertible notes payable to third parties for a total of $14,500. The notes are all unsecured, non-interest bearing and due and payable in six months. If the loans are not repaid by the due date they can be converted into shares of common stock at $0.25 per share. In addition, the Company issued warrants to purchase 20,669 shares of common stock. The warrants have an exercise price of $0.50 and expire in five years.

The above notes are shown net of $3,451 of debt discount. 

XML

RELATED PARTY TRANSACTIONS

9 Months Ended

Sep. 30, 2020

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

NOTE 6 – RELATED PARTY TRANSACTIONS

Marla Palumbo has advanced the Company a limited amount of funds to cover some general operating expenses and travel costs. These advances are unsecured, due on demand and non-interest bearing. As of September 30, 2020, and December 31, 2019, the balance due to Ms. Palumbo for cash advances is $22,670 and $9,498, respectively. Ms. Palumbo is the President of the Company and wife of the CEO, Mark Palumbo.

During the nine months ended September 30, 2020 and 2019, the Company paid sales commissions of $12,900 and $23,962, respectively, to EME Ltd.

During the nine months ended September 30, 2020 and 2019, respectively, the Company incurred $0 and $7,450 of expense for Matthew Palumbo for product design services. Matthew Palumbo is the son of Mark Palumbo, CEO.

On April 29, 2019, the Company entered into a Technology License Agreement with Mark Palumbo (“Licensor”) whereby the Licensor granted to the Company an exclusive worldwide license (the “License”) to use, market, promote and distribute certain technology related to a provisional patent application for a “Process for creating Carbohydrate Complexes with Cannabinoids and other Hydrophobic Molecules in large scale,” related patent applications, related trade-secrets and associated knowhow, including methods, techniques, specifications, procedures, information, systems, knowledge and business processes required to practice and carry on business in the field of data collection, security and management (the “Technology”). The initial term of the License is 5-years (the “Initial Term”) and shall automatically be renewed for successive 1-year terms (each, a “Renewal Term”) unless the Company elects to terminate the License by giving 30 days’ written notice prior to commencement of a Renewal Term. In exchange for the License of the Technology, the Company shall issue to the Licensor 5,000,000 restricted shares of its common stock, valued at par value per share, at the effective date of the agreement, and shall issue to the Licensor an additional 1,000,000 restricted shares of its common stock, valued at par value per share, at the commencement of each Renewal Term.

On March 30, 2020, the Company issued 1,000 shares of its Series A Preferred Stock to Mark Palumbo, an officer and director of the Company. Based on the rights of the designation the shares of preferred stock were value at 60% of the value of the total common stock outstanding. The shares of common stock have a current fair value of $0.25 per shares resulting in total non-cash expense of $2,765,250.

XML

PREFERRED STOCK

9 Months Ended

Sep. 30, 2020

Preferred Stock

PREFERRED STOCK

NOTE 7 – PREFERRED STOCK

The Company has designated 1,000 shares of Series A Preferred Stock. The shares of Series A Preferred Stock have a par value of $0.0001 per share. The Series A Preferred Shares do not have a dividend rate or liquidation preference and are not convertible into shares of common stock. Series A Preferred Stock, voting together as a class, have the right to vote 60% of the Company’s voting shares on any and all shareholder matters (the “Majority Voting Rights”). Additionally, the Company shall not adopt any amendments to the Company’s Bylaws, Articles of Incorporation, as amended, make any changes to the Certificate of Designations establishing the Series A Preferred Stock, or effect any reclassification of the Series A Preferred Stock, without the affirmative vote of at least a majority of the outstanding shares of Series A Preferred Stock. However, the Company may, by any means authorized by law and without any vote of the holders of shares of Series A Preferred Stock, make technical, corrective, administrative or similar changes to such Certificate of Designations that do not, individually or in the aggregate, adversely affect the rights or preferences of the holders of shares of Series A Preferred Stock. Other than the Majority Voting Rights, the Series A Preferred Stock does not have any other dividend, liquidation, conversion, or redemption rights, whatsoever. 

XML

WARRANTS

9 Months Ended

Sep. 30, 2020

Recent Accounting Standards

WARRANTS

NOTE 8 – WARRANTS

On April 1, 2020, the Company entered into an agreement with an independent consultant pursuant to which the consultant shall be paid a cash monthly retainer of $5,000 a month and shall be issued 110,000 warrants to purchase shares of the common stock of the Company at an exercise price equal to $0.25 per share, subject to certain conditions regarding vesting. This agreement has a term of 12 months and shall be automatically renewed on a month to month basis unless terminated upon 30 days’ written notice.

The warrants were evaluated for purposes of classification between liability and equity. The warrants do not contain features that would require a liability classification and are therefore considered equity. The warrants were fair valued at $25,038. The expense is being amortized over the one-year term of the agreement. The Black Scholes pricing model was used to estimate the fair value of the Warrants issued with the following inputs:

Warrants		110,000
Share price	$	0.25
Exercise Price	$	0.25
Term		10 years
Volatility		103.5	%
Risk Free Interest Rate		2.49	%
Dividend rate		-

During the nine months ended September 30, 2020, the Company issued 40,836 warrants in conjunction with the issuance of convertible promissory notes (Note 5). The warrants have an exercise price of $0.50 and expire in five years. Using the fair value calculation, the relative fair value between the debt issued and the warrants was calculated to determine the warrants recorded equity amount of 6,212, accounted for in additional paid in capital.

The Black Scholes pricing model was used to estimate the fair value of the warrants issued with the following inputs: 

Warrants		40,836
Share price	$	0.25
Exercise Price	$	0.25
Term		5 years
Volatility		103.5 – 111.89	%
Risk Free Interest Rate		0.22 - 1.88	%
Dividend rate		-

A summary of the status of the Company’s outstanding stock warrants and changes during the year is presented below:

Activity for the nine months ended September 30, 2020 is as follows: 

	Number of Warrants		Weighted Average Exercise  Price		Weighted Average Remaining Contract Term		Aggregate  Intrinsic  Value
Outstanding at December 31, 2019	-		-		-
Granted		150,836	$	0.25		8.22	$	-
Expired		-	$	-		-	$	-
Exercised		-	$	-		-	$	-
Outstanding at September 30, 2020		150,836	$	0.25		8.22	$	-
Exercisable at September 30, 2020		76,000	$	0.25		8.22	$	-

Range of Exercise Prices		Number Outstanding 9/30/2020		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price
$	0.25		150,836		8.22 years	$	0.25

XML

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2020

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 9 – SUBSEQUENT EVENTS

In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were available to be issued and has determined that it does not have any material subsequent events to disclose in these financial statements. 

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Accounts Receivable

Accounts Receivable

Revenues that have been recognized but not yet received are recorded as accounts receivable. Losses on receivables will be recognized when it is more likely than not that a receivable will not be collected. An allowance for estimated uncollectible amounts will be recognized to reduce the amount of receivables to its net realizable value when needed. The allowance for uncollectible amounts is evaluated quarterly.

Revenue Recognition

Revenue Recognition

Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time, typically upon delivery.

The Company recognizes revenue when product is shipped. The Company will often receive payment and/or pay for the cost of goods prior to shipping. When this occurs, the result is both a prepaid for the supplies to be used in their product and a customer deposit. As of December 31, 2019, the Company has both a prepaid expense of $4,145 and customer deposits of $54,660, for orders to be shipped in Q1, 2020.

Cost of Sales

Cost of Sales

Cost of sales is determined on the basis of the cost of production or the purchase of goods, adjusted for the variation of inventory Cost of sale is recognized as the direct cost of products or services sold during the period.

Recent Accounting Standards

Recently issued accounting pronouncements

The Company has implemented all new accounting pronouncements that are in effect.  These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. 

XML

WARRANTS (Tables)

9 Months Ended

Sep. 30, 2020

Recent Accounting Standards

Schedule of estimated the fair value of these warrants using Black-Scholes

The Black Scholes pricing model was used to estimate the fair value of the Warrants issued with the following inputs:

Warrants		110,000
Share price	$	0.25
Exercise Price	$	0.25
Term		10 years
Volatility		103.5	%
Risk Free Interest Rate		2.49	%
Dividend rate		-

The Black Scholes pricing model was used to estimate the fair value of the warrants issued with the following inputs: 

Warrants		40,836
Share price	$	0.25
Exercise Price	$	0.25
Term		5 years
Volatility		103.5 – 111.89	%
Risk Free Interest Rate		0.22 - 1.88	%
Dividend rate		-

Schedule of outstanding stock warrants and changes

Activity for the nine months ended September 30, 2020 is as follows: 

	Number of Warrants		Weighted Average Exercise  Price		Weighted Average Remaining Contract Term		Aggregate  Intrinsic  Value
Outstanding at December 31, 2019	-		-		-
Granted		150,836	$	0.25		8.22	$	-
Expired		-	$	-		-	$	-
Exercised		-	$	-		-	$	-
Outstanding at September 30, 2020		150,836	$	0.25		8.22	$	-
Exercisable at September 30, 2020		76,000	$	0.25		8.22	$	-

Schedule of weighted average remaining

Range of Exercise Prices		Number Outstanding 9/30/2020		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price
$	0.25		150,836		8.22 years	$	0.25

XML

DESCRIPTION OF BUSINESS AND HISTORY (Details Narrative) - $ / shares			9 Months Ended
	Jul. 12, 2018	Jun. 18, 2018	Sep. 30, 2020
Number of shares cancelled		20,000,000
Number of shares issued		3,000,000
Redemption shares of stock		20,000,000
Percentage of total outstanding common stock		100.00%
Description of produces and sells			CannAssist produces and sells products formulated using its cannabidiol ("CBD") product, “Cibidinol,” which is formulated based on a process developed by its founder Mark Palumbo.
Exchange Acquisition Agreement [Member] | Xceptor LLC [Member]
Number of shares exchange in business acquisition	3,000,000
Business acquisition, share price (in dollars per share)	$ 0.0001

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Prepaid expenses	$ 4,308	$ 4,145
Customer deposits		$ 54,660

XML

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenues							$ 679,050
Net income (loss)	$ 38,921	$ (83,570)	$ (2,775,369)	$ (80,828)	$ (250,563)	$ (36,150)	(2,820,018)	$ (367,541)
Non-cash stock compensation expense							2,765,250
Accumulated deficit	$ (3,242,530)						$ (3,242,530)		$ (422,512)

XML

LOANS PAYABLE (Details Narrative) - Third Party [Member] - Unsecured Loan Payable [Member] - USD ($)					2 Months Ended
	Jun. 29, 2020	Jun. 12, 2020	Jun. 02, 2020	Oct. 11, 2017	Aug. 31, 2020
Proceeds from unsecured loan payable	$ 10,000			$ 1,000
Interest rate terms	non-interest bearing	non-interest bearing	non-interest bearing	non-interest bearing	non-interest bearing

XML

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)					2 Months Ended	3 Months Ended
	Jun. 29, 2020	Jun. 12, 2020	Jun. 02, 2020	Oct. 11, 2017	Aug. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Apr. 02, 2020	Dec. 31, 2019
Number of warrant issued						$ 9,710	$ 9,022
Debt discount						$ 3,451
Warrant [Member]
Exercise price (in dollars per share)								$ 0.25
Warrant term						8 years 2 months 19 days		12 months	8 years 2 months 19 days
Third Party [Member] | Unsecured Loan Payable [Member]
Convertible note payable		$ 5,000	$ 10,000		$ 14,500
Interest rate terms	non-interest bearing	non-interest bearing	non-interest bearing	non-interest bearing	non-interest bearing
Debt term		6 months	6 months		6 months
Debt conversion price (in dollars per shares)		$ 0.25	$ 0.25		$ 0.25
Third Party [Member] | Unsecured Loan Payable [Member] | Warrant [Member]
Number of warrant issued		$ 6,667	$ 13,500		$ 20,669
Exercise price (in dollars per share)		$ 0.50	$ 0.50		$ 0.50
Warrant term		5 years	5 years		5 years

XML

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)				3 Months Ended		9 Months Ended
	Mar. 30, 2020	Apr. 29, 2019	Jun. 18, 2018	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Commissions - related party				$ 8,527	$ 11,395	$ 12,900	$ 23,962
Number of shares issued (in shares)			3,000,000
Common stock, par value (in dollars per share)				$ 0.0001		$ 0.0001		$ 0.0001
Non-cash stock compensation expense						$ 2,765,250
Series A Preferred Stock [Member]
Preferred stock, voting rights						Series A Preferred Stock, voting together as a class, have the right to vote 60% of the Company’s voting shares
Technology License Agreement [Member] | Mr. Mark Palumbo [Member]
License initial term		5 years
Automatically renewed terms		1 year
Technology License Agreement [Member] | Restricted Shares [Member] | Mr. Mark Palumbo [Member]
Number of shares issued (in shares)		5,000,000
Number of shares issued at each renewal term (in shares)		1,000,000
Mr. Matthew Palumbo [Member]
Expenses related party transaction						$ 0	7,450
EME Ltd. [Member]
Commissions - related party						12,900	$ 23,962
Ms. Marla Palumbo [Member] | General Operating Expenses [Member]
Due to related party				$ 22,670		$ 22,670		$ 9,498
Mr. Mark Palumbo [Member] | Series A Preferred Stock [Member]
Number of shares issued (in shares)	1,000
Preferred stock, voting rights	Based on the rights of the designation the shares of preferred stock were value at 60% of the value of the total common stock outstanding.
Common stock, par value (in dollars per share)	$ 0.25
Non-cash stock compensation expense	$ 2,765,250

XML

PREFERRED STOCK (Details Narrative) - $ / shares	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Number of shares designated	20,000,000	20,000,000
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Series A Preferred Stock [Member]
Number of shares designated	1,000
Preferred stock, par value (in dollars per share)	$ 0.0001
Preferred stock, voting rights	Series A Preferred Stock, voting together as a class, have the right to vote 60% of the Company’s voting shares

XML

WARRANTS (Details)	9 Months Ended
	Sep. 30, 2020 $ / shares shares
Warrant 1 [Member]
Warrants | shares	110,000
Share price	$ 0.25
Exercise Price	$ 0.25
Term	10 years
Volatility	103.50%
Risk Free Interest Rate	2.49%
Dividend rate
Warrant 2 [Member]
Warrants | shares	40,836
Share price	$ 0.25
Exercise Price	$ 0.25
Term	5 years
Dividend rate
Warrant 2 [Member] | Minimum [Member]
Volatility	103.50%
Risk Free Interest Rate	0.22%
Warrant 2 [Member] | Maximum [Member]
Volatility	111.89%
Risk Free Interest Rate	1.88%

XML

WARRANTS (Details 1) - Warrant [Member]	9 Months Ended
	Sep. 30, 2020 $ / shares shares
Number of Warrants
Outstanding at beginning | shares
Granted | shares	150,836
Expired | shares
Exercised | shares
Outstanding at end | shares	150,836
Exercisable at end | shares	76,000
Weighted Average Exercise Price
Outstanding at beginning | $ / shares
Granted | $ / shares	0.25
Expired | $ / shares
Exercised | $ / shares
Outstanding at end | $ / shares	0.25
Exercisable at end | $ / shares	$ 0.25
Weighted Average Remaining Contract Term
Outstanding at beginning	8 years 2 months 19 days
Weighted average remaining contract term	8 years 2 months 19 days
Weighted average remaining contract term, exercisable	8 years 2 months 19 days

XML

WARRANTS (Details 2) - Warrant [Member] - $ / shares	Sep. 30, 2020	Apr. 02, 2020	Dec. 31, 2019
Exercse Price		$ 0.25
Number outstanding		110,000
Weighted average remaining contractual life (years)	8 years 2 months 19 days	12 months	8 years 2 months 19 days
Exercise Price $0.25 [Member]
Exercse Price	$ 0.25
Number outstanding	150,836
Weighted average remaining contractual life (years)	8 years 2 months 19 days
Weighted Average Exercise Price	$ 0.25

XML

WARRANTS (Details Narrative) - USD ($)		9 Months Ended
	Apr. 02, 2020	Sep. 30, 2020	Dec. 31, 2019
Cash		$ 57,421	$ 80,021
Warrant [Member]
Cash	$ 5,000
Number of warrant issued	110,000
Exercise price (in dollars per share)	$ 0.25
Warrant term	12 months	8 years 2 months 19 days	8 years 2 months 19 days
Warrant terminated term	automatically renewed on a month to month basis unless terminated upon 30 days’ written notice.
Warrant 1 [Member]
Number of warrant issued		110,000
Exercise price (in dollars per share)		$ 0.25
Warrant term		10 years
Description of warrant issued		The expense is being amortized over the one-year term of the agreemen
Warrant fair value		$ 25,038
Warrant 2 [Member]
Number of warrant issued		40,836
Exercise price (in dollars per share)		$ 0.25
Warrant term		5 years
Warrant 2 [Member] | Two Convertible Promissory Note [Member]
Number of warrant issued		40,836
Exercise price (in dollars per share)		$ 0.50
Warrant term		5 years
Warrant fair value		$ 6,212